陈有海,免疫学博士,欧洲科学院 (Academia Europaea) 院士,美国医学与生物工程院(AIMBE) Fellow。现任深圳理工大学讲席教授、药学院院长;中国科学院深圳先进技术研究院医药所癌症免疫研究中心主任。曾任美国宾夕法尼亚大学病理学和实验医学系终身教授,宾夕法尼亚大学医学院教学委员会主席,美国多发神经硬化基金会科学委员会主席等职务。入选全球前1%顶尖科学家终身影响力榜单,美国Kunkel学会会士(Elected Member),雷顿奖(Colyton Prize)获奖人。 陈有海教授主要从事癌症、炎症机制和治疗的研究,在免疫应答的调节、免疫性疾病的发病机制及治疗、新免疫检查点药物在癌症治疗中的应用等诸多领域取得显著的成就。在Science, Cell, Nature, Nature Immunology, Nature Cancer等国际权威杂志发表学术论文160余篇(截止到2022年H因子68;i10因子135;文章总引用次数>20000)。
Lab Features
本实验室运用非传统思维、跨学科手段,立足癌症免疫基础研究,利用智能药物设计和生物制药前沿技术开发一批针对特异靶点的抗癌新药。本实验室涉及的研究领域包括癌症生物学,免疫学,药理学,药效学,微生物学,基因、蛋白、药物组学,生物制药,癌症疫苗,基因治疗,药物安全评价,药物临床试验等。
Lab Achievements
1. 首次发现并鉴定了粘膜调节性T细胞。2. 首次发现并鉴定了TIPE家族的三个成员。3. 首次发现Rel/NF-kB家族在炎症和癌症中关键作用。4. 首次研发出能治疗肝衰竭的抗体候选药物AS1501。
Lab Training
现有助理研究员2名,博士后6名,博士生1名,硕士生1名。
陈有海课题组的长期科研目标是围绕着3个一脉相承的问题,通过研发新 方法、新技术从而实现突破性进展:


I. Genes and Genomics of Autoimmune Inflammation. A major goal of Dr. Chen’s research program is to understand the molecular mechanisms of inflammatory diseases (such as multiple sclerosis and type 1 diabetes) and to find a cure for these diseases. Although the etiological factors that trigger these diseases vary, the common pathological outcome of autoimmune diseases is the destruction of self-tissues by activated lymphoid and myeloid cells through a process called autoimmune inflammation. Development of autoimmune inflammation requires coordinated expression of myriad genes that mediate the activation, migration and effector functions of inflammatory cells. These include genes that encode antigen receptors, costimulatory molecules, cytokines, chemokines, and cytotoxic enzymes. To explore the spectrum and global patterns of gene expression during autoimmune inflammation, Dr. Chen’s laboratory has performed functional genomic studies of autoimmune inflammation in the central nervous system (CNS). Inflammation in the CNS not only induced the expression of many immune-related genes, but also significantly altered the gene expression profile of neural cells. A number of unique clusters of genes were identified which represent putative immune and nervous responses in autoimmune inflammation. Using models of inflammation, Dr. Chen and colleagues are exploring the physiological and pathological roles of the following genes: the Rel/nuclear factor (NF)-kB family, microRNA-21, and Pdcd4. The following questions are being examined: 1) What are the roles of these genes in the activation, differentiation, and effector function of inflammatory cells following antigen or Toll-like receptor activation? 2) What are the roles of these genes in the death of lymphoid cells, myeloid cells, oligodendrocytes and pancreatic beta cells?

II. Inflammation, Cancer, and the TIPE Family. The connection between cancer and inflammation is widely recognized, yet the underlying molecular mechanisms are poorly understood. By genomic profiling of inflamed tissues, Dr. Chen and colleagues discovered in 2002 three members of the TIPE (TNF-alpha-induced protein 8-like) family. They have since crystallized two of them and generated mice deficient in three of them. They discovered that TIPE family plays crucial roles in both inflammation and cancer, and provides a molecular bridge between inflammation and cancer by targeting signaling molecules shared by them. Dr. Chen and colleagues are investigating the molecular mechanisms of TIPE action in immunity, inflammation, and cancer, and new TIPE-based strategies to treat inflammation and cancer.

III. Immunotherapy and Gene Therapy. Targeting Rel and TIPE genes, Dr. Chen and colleagues are exploring the potential of gene therapy approaches for the treatment of cancer and autoimmune diseases.